The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Veracyte; Viatris
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Veracyte; Viatris
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Veracyte; Viatris
Travel, Accommodations, Expenses - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Veracyte; Viatris
Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).
 
Rachel Wuerstlein
No Relationships to Disclose
 
Paul Ellis
No Relationships to Disclose
 
Filippo Montemurro
Honoraria - Roche
Consulting or Advisory Role - Lilly; Novartis; Pierre Fabre; Seagen
Speakers' Bureau - AstraZeneca; Pfizer
 
Antonio Antón Torres
Consulting or Advisory Role - Bayer
Expert Testimony - Pfizer
 
Suzette Delaloge
Consulting or Advisory Role - AstraZeneca (Inst); Pierre Fabre (Inst)
Research Funding - AstraZeneca (Inst); Exact Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Qingyuan Zhang
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Shusen Wang
No Relationships to Disclose
 
Shao Zhimin
No Relationships to Disclose
 
Huiping Li
No Relationships to Disclose
 
Andhika Rachman
No Relationships to Disclose
 
Mawin Vongsaisuwon
No Relationships to Disclose
 
Haiying Liu
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Genentech/Roche
 
Simon Fear
Employment - Roche
 
Claudia Pena-Murillo
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Carlos H. Barrios
Stock and Other Ownership Interests - Biomarker; MedSIR; Tummi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science (Inst); Abbvie (Inst); Abraxis BioScience (Inst); Amgen (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clinica Atlantis (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); ImClone Systems (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen (Inst); LEO Pharma (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merrimack (Inst); Millennium (Inst); Mylan (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst); Shanghai Henlius Biotech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech